MCC Global New

Über Equus Total Return Inc.

http://www.etfconnect.com/select/fundpages/...nd%20Holdings%20Summary

Über Infinia im TV:

http://www.infiniacorp.com/about/video/clip_kvew1.htm

News zu Infinia:

http://www.bosch-thermotechnology.com/sixcms/detail.php/2381690

MCC Europe Ltd  ist zu dem mit 1,805,625 Aktien also zu 3.41% an Valirx beteiligt.

Siehe http://www.valirx.com/

Aussage vom Chairman:

Against this backdrop, your Board believes the Company is now well on track to generate first revenues from its range of diagnostic and drug research products in early 2009, and to continue advancing its principal therapeutics platform, GeneICE following the recently announced success of in vivo studies.  

Look at this http://www.equuscap.com/management_mcca.htm  

 

Habe mir heute mal die Equus genauer angeschaut.

Im Verhältnis zu Nasdaq Composite und S&P 500 schneidet Equus wesentlich besser ab.  

Siehe http://finance.sfgate.com/...UID=6406169&Page=MediaViewer&Ticker=ZION  

http://www.youtube.com/watch?v=c_uSJl0-Wfc  

Bericht vom 15.08.2008

http://www.kvewtv.com/index.php?story_id=7574
 

http://www.infiniacorp.com/about/great_news.php#  

Laut den Ausführungen im Netz ist MCC Global zu 40% an diesem Unternehmen beteiligt!
In den Präsentationsfolien, die mal im Web auftauchten, wurde diese als Case Study aufgeführt.

Diese Firma bietet Produkte für SOA (Service Oriented Architectures) an.
Namhafte Kunden sind anscheinend Global Player mit bis zu mehreren Millarden von Umsätzen u.a. General Electric, Vodaphone, Cisco, Prudential, US Cellular, BT Global Services, Royal Bank of Scotland, Wolters Kluwer

Quelle: http://ignitexml.com/  

Ich bin mir ziemlich sicher, dass wir für 2008 vielleicht noch nicht mit Gewinnen rechnen können.
Bei den Deals, die MCC seit 2007 macht, sollte dieses Unternehmen spätestens Ende 2009 bzw. Anfang 2010 der Renner werden. Allerdings ist das meine subjektive Meinung!

MCC ist derzeit eine hochspekulative Aktie. Der Kurs spricht nicht unbedingt für Vertrauen. Genauso wenig sind die Terminverschiebungen bzgl. der Bilanzen vertrauenserweckend. Eine Umstellung der Bilanzen auf IRFS ist auf der anderen Seite kein Kinderspiel vor allem für eine Beteiligungsfirma wie MCC Global NV.
Ethan Weyand wurde auch meines Wissens erst seit Ende 2007 für diese Aufgaben als CFO vorgesehen.

Durch die Shareholder-Beteiligung an Equus hat die Company bewiesen, dass sie durchaus Gewinne erwirtschaften kann. Sollte das Management bessere Zahlen als 2007 vorlegen, so werden wir mit dem Kurs
nach eine Richtung nach oben kennen. Und falls nicht, würde ich weiterhin investiert bleiben, da die Aussichten aufgrund der Phantasie der Beteiligungen nur euphorisch sein können.  

HOUSTON, Sept. 17 /PRNewswire-FirstCall/ -- Equus Total Return, Inc. (NYSE: EQS) (the "Fund") has repurchased an aggregate of 423,960 shares of its common stock, representing 4.9% of its outstanding shares, from unaffiliated third parties in a private transaction. In compliance with federal law, the sale was effected at the shares' market price computed as the 5-day volume-weighted average closing price prior to the date of sale, which was September 11, 2008. The shares were repurchased at a discount to the Fund's net asset value and subsequently retired. This increased the net asset value per share (as adjusted for cash and share dividends to be paid in the third quarter) from approximately $11.78 to $12.02.

In the Fund's quarterly report for the period ended June 30, 2008, in its last annual report mailed to shareholders on or about April 30, 2008, and in other public documents, the Fund informed shareholders of its intention to possibly repurchase a portion of its stock. The disclosures stated that the Board of Directors has determined that it would be in the best interest of the stockholders for the Fund to be authorized to attempt to reduce or eliminate the market value discount from net asset value. Accordingly, from time to time the Fund may, but is not required to, repurchase its shares in an attempt to reduce or eliminate the discount or to increase the net asset value of the remaining shares.

Discussing the present share repurchase, Kenneth I. Denos, the Fund's CEO and President, commented that: "With the Fund's shares currently trading at a significant discount from their net asset value, we viewed the share repurchase as a prudent use of the Fund's resources."

The Fund's share repurchase was not made in a manner or on a basis which discriminates unfairly against any Fund shareholders.

Equus Total Return, Inc. is a business development company that trades as a closed-end fund on the New York Stock Exchange, under the symbol "EQS". Additional information on Equus Total Return, Inc. may be obtained from the Equus website at http://www.equuscap.com.  

WASHINGTON, D.C.: The U.S. Department of Energy (DOE) has selected 15 new projects for negotiations of award under the Funding Opportunity Announcement (FOA), Advanced Heat Transfer Fluids and Novel Thermal Storage Concepts for Concentrating Solar Power Generation.



These projects will facilitate the development of lower-cost energy storage for concentrating solar power (CSP) technology. CSP systems use heat generated by concentrating and absorbing the sun's energy to produce electric power.



These projects are expected to promote DOE's goal of reducing the cost of CSP electricity from 13 to 16 cents/kWh today with no storage to eight to 11 cents/kWh with six hours of storage by 2015 and to less than seven cents/kWh with 12 to 17 hours of storage by 2020.



DOE has selected seven companies and six universities for funding under this award. DOE will provide up to US$35 million over four years, subject to annual appropriations; with cost-share, the total public-private investment will be up to approximately US$67.6 million for the selected projects.



Companies selected include Symyx of Sunnyvale, Calif.; Abengoa of Lakewood, Colo.; Acciona of Henderson, Nev.; General Atomics of San Diego, Calif.; Infinia Corporation of Kennewick, Wash.; Terrafore of Riverside, Calif.; and U.S. Solar Holdings of Boise, Idaho.



Universities selected include City University of New York in New York City; Lehigh University of Bethlehem, Penn.; Texas Engineering Experiment Station at Texas A&M University in College Station, Texas; University of Alabama at Tuscaloosa; University of Arkansas at Fayetteville; and University of Connecticut, Storrs, Conn.



The projects support President George W. Bush's Solar America Initiative, which aims to make solar energy cost competitive.


Quelle: http://www.energycurrent.com/index.php?id=3&storyid=13247  

Infinia Corporation – Innovative Application of Maintenance Free Phase Change Thermal Energy Storage for Dish Engine Solar Power Generation (Kennewick, Wash.) Infinia will demonstrate the practicality of integrating a thermal energy storage module with a dish stirling engine, enabling the system to operate during cloud transients and to provide dispatchable power for four to six hours after sunset. Infinia will demonstrate the concept on 40-50 dish-engine systems at DOE’s Sandia National Laboratories. (Up to $9.4 million)

Quelle: http://www.northcoastoregon.com/articles/...ar_power_storage_by_2015/  

Times & Sales
Zeit Kurs  Stück  
15:05:19 0,005  3.000.000  

ValiRx licenses prostate cancer candidate from CRT
Science|Business


Licensing agreement

Cancer therapeutics and diagnostics company ValiRx has struck a licensing deal with Cancer Research Technology Ltd, the commercialisation arm of Cancer Research UK, to evaluate a novel prostate cancer compound, coded VAL201, that has been found preclinical tests to arrest the growth of prostate cancer.

ValiRx now has a period of 12 months in which to complete the preclinical regulatory development of VAL201, including toxicology, before exercising its option to acquire exclusive worldwide rights to the compound as an anticancer agent and later progress to clinical trials.

Annual global sales of prostate cancer drugs are estimated to be $3 billion. In the UK alone, 35,000 men are diagnosed with prostate cancer each year: early detection gives the best chance of survival, yet presently the tumour claims 10,000 lives annually.

ValiRx believes that VAL 201 has the potential to add significant value, provided the compound reaches the remaining preclinical and clinical milestones. Early studies have thus far indicated that this lead drug candidate may also stop tumour growth in patients who fail to respond to current treatments.

Satu Vainikka, CEO of ValiRx, commented: “This agreement further extends our relationship with Cancer Research Technology and expands our portfolio of late pre-clinical compounds. If successful, VAL 201 could offer the potential for novel treatment approaches to prostate cancer treatment where there is currently unmet need.“

Dr Phil L’Huillier, Cancer Research Technology’s director of business management, said: “We are very pleased to enter into an agreement for ValiRx to take forward into preclinical development this promising compound for the potential treatment of men with hormone resistant prostate cancer.”

 

16 September 2008, London. ValiRx (AIM: VAL, "ValiRx", "the Company"), the cancer therapeutics and diagnostics company, has announced that its diagnostics division in Belgium ("ValiBio") is now progressing a prototype Nucleosomics™ cancer detection test to the next stage of development, which will include testing patient blood samples. If successful, the test could pave the way for non-invasive tests for early cancers based on detecting "epigenetic" histone modifications in blood samples that correlate with a specific cancer.




The first prototype test, based on ValiRx's proprietary technology, has already been shown to provide a quantitative measure of epigenetic histone modifications in blood samples using standard laboratory ELISA methodology. Further prototype tests for other histone modifications are now planned over the next three months. Research currently suggests the de-regulation of normal epigenetic control mechanisms is implicated in the development and progression of certain cancers.




The Nucleosomics™ diagnostic technology has been developed to measure specific histone modifications which have been shown to correlate with certain cancers. Unlike other epigenetic cancer tests in development, ValiBio's prototype tests use simple, low cost and established high-throughput ELISA technology, which means the tests can be performed on standard instrumentation available in all pathology laboratories.




ValiBio now plans to use this first prototype test, as well as further prototype tests with blood samples from patients who have been positively diagnosed with cancer to determine the diagnostic predictive correlation of the kits. Collaborations have been set up between ValiBio and hospitals in Germany and Belgium. If the correlations are positive, the Company will proceed to a wider patient sample study over several months. It is anticipated the first test could be launched by ValiBio within the next fifteen months.




Dr Satu Vainikka ValiRx's Chief Executive said:




"The Nucleosomics test will meet the large unmet medical need for non-invasive early cancer detection to improve patient outcomes. Many of the indications we hope to diagnose are often detected too late for effective treatment. This is especially true of colon and pancreatic cancers that progress without obvious symptoms".  




The market for in vitro cancer diagnostics is estimated at US$5 billion, growing at 11% per annum*




* Source: IVD Technology May 2008, http://www.devicelink.com/ivdt/archive/08/05/003.html  

Folgende News könnt Ihr bei http://de.babelfish.yahoo.com/ übersetzen

http://www.lavozdigital.es/cadiz/20080924/...a-poligono-20080924.html  

Notiert derzeit bei 4.875 GBP!!!

Wechselkurs:
1 EURO kostet 0,79 Britisches Pfund
1 Britisches Pfund kostet 1,26 EURO


Siehe http://www.londonstockexchange.com/en-gb/...earch.htm?bsg=true&ns=VAL  

Der Präsidentenschaftskandidat liegt derzeit wg. aktueller Krise mit 9% vor McCain.
Da die Strategie von MCC Global auf erneuerbare Energien ausgerichtet wurde, wird Obama für das Wachstum von MCC ein "Katalysator" werden ,-)  

Zum Alternative Energy User Group meeting wurde im Januar eine Präsentationsfolie erstellt, der das Potential von Infinia für MCC deutlich macht:

http://maccompanion.com/RenewableEnergy/Presentations/Infinia.pdf  

Bluewater Bio International enters into definitive agreement with Zero Waste Technology as exclusive representative for the Kingdoms of Bahrain, Jordan, Kuwait and Saudi Arabia


http://www.londonstockexchange.com/LSECWS/...px?id=1952690&source=RNS  

Bin mir jetzt gar nicht so sicher...
Es gibt auch eine Website in Neuseeland...

Hat jemand eine Idee?  

http://community.investopedia.com/news/IA/2008/...A_Discount_EQS.aspx  

In den nächsten Tagen wird der Kurs zwischen 0,004 und 0,006 schwanken bis der nächste Run einsetzt ,-)  

Siehe http://www.newsguide.us/technology/information/...am/?date=2008-10-10